DUBLIN, October 17, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Circulating Tumor Cell, Cell Free DNA, Exosome and Vesicle Cancer Diagnostic Markets 2016 including Screening Market - Potential Sizing" report to their offering.

The Diagnostic, Monitoring and Screening Test opportunities are explored.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls.  Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. 

Key Topics Covered:

1. Introduction and Market Definition

1.1 What is Liquid Biopsy?

1.2 The Genetics Revolution

1.3 Market Definition

1.4 Methodology

1.5 Liquid Biopsy and Clinical Laboratory Testing - Spending Perspective

2. Market Overview

2.1 Market Participants

2.2 Conditions Identified with Biopsies

2.3 Biopsy Sites

2.4 Analysis of Biopsied Material

2.5 Evidence of Cancer - Liquid Biopsy Technology

2.6 Changing the Cancer Treatment Protocol

2.7 Industry Structure

2.8 Profiles of Key Liquid Biopsy Companies

3. Market Trends

3.1 Factors Driving Growth

3.2 Factors Limiting Growth

3.3 Instrumentation and Automation

3.4 Diagnostic Technology Development

4. Liquid Biopsy Recent Developments

4.1 Recent Developments - Importance and How to Use This Section

4.2 Illumina Forms GRAIL to Enable Early Cancer Detection via Liquid Biopsy

4.3 ASCO: Researchers Present Advances, Ongoing Challenges in Liquid Biopsy

4.4 Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study

4.5 Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen

4.6 Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test

4.7 Baylor, TGen Collaborate on Personalized Cancer Treatment Options

4.8 Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab

4.9 Broad Institute Lands $10M Gift to Study Cancer Drug Resistance

4.10 Biocept Q1 Revenues Rise With Test Volume Growth

4.11 CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers

4.12 New Oncology Closes Financing Round to Promote Genetic Testing from Blood

4.13 Cynvenio to present new clinical data

4.14 EKF, Angle Collaborate for Liquid Biopsy Development

4.15 Trovagene Collaborates with UCSD for EGFR Monitoring in Lung Cancer

4.16 AstraZeneca Initiates CDx Partnerships with Roche, Qiagen

4.17 Horizon, LGC Awarded Research Grant for Cancer Diagnostics

4.18 Merck Serono and Sysmex Inostics Announce Testing Center

4.19 Agena Bioscience Launches Smaller Format MassArray

4.20 Personal Genome Diagnostics Aims for FDA Clearance

4.21 HTG Molecular Diagnostics Files for IPO of up to $60M

4.22 Genomic Health Reports 5 Percent Revenue Growth in Third Quarter

4.23 Biocept, Rosetta Genomics Partner to Profile microRNAs from CTCs

4.24 Inivata Raises $6.6M to Develop ctDNA Assays

4.25 Epic Sciences Raises $30M in Private Financing

4.26 New Release in Line of Liquid Biopsy CLIA Tests

4.27 Collaborators Publish Data on Resolution Bio Liquid Biopsy Test

4.27 Trovagene's Urine-Based Liquid Biopsy Platform Demonstrated in Field

4.28 FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test

4.29 DNA in blood can track cancer development, response in real time

4.30 Cynvenio Clinical Trial Supports Multi-Template Liquid Biopsy Sequencing

4.31 Startup AccuraGen to Tap China Liquid Biopsy Market With 61-Gene Assay

4.32 Sysmex Corporation and Clearbridge BioMedics to Jointly Develop New Liquid Biopsy System

4.33 MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States

4.34 GATC Biotech's Liquid Biopsy Testing Takes Cost Lead

4.35  Liquid Biotech USA, Inc. Announces Completion of  Clinical Study

4.36 Liquid biopsies more effective in some cases than tissue biopsies

4.37 Cancer Genetics, Inc. and ApoCell Announce Partnership for Rare Cell Capture and Detection

4.38 Exosome Diagnostics Launches Liquid Biopsy Test to Rule Out High-Grade Prostate Cancer

4.39 Liquid Biopsy Tests Partially Validated

4.40 FDA Approves Liquid Biopsy

4.41 Liquid Biopsy Predicts Colon Cancer Recurrence

4.42  WaveSense Receives CE-IVD Mark for Cell Enrichment Platform

4.43  For Liquid Biopsy, Size Matters

4.44 Liquid biopsy startup Freenome lands $5.5 million led by Andreessen Horowitz

4.45  Trovagene, USC Collaborate on Deployment of Urine-Based Liquid Biopsy Test

4.46  Circulogene liquid biopsy detects new tumor mass earlier than current imaging methods

5.  Country Market Sizes - North America

5.1 United States of America

5.2 Canada

6. Country Markets - Europe

6.1 France

6.2 Germany

6.3 United Kingdom

6.4 Spain

6.5 Italy

6.6 Russia

6.7 Remainder of Europe and Former Soviet Union

7. Country Markets - Asia Pacific

7.1 China

7.2 Japan

7.3 South Korea

7.4 India

7.5 Australia

7.6 Rest of Asia Pacific

8. Country Markets - Latin America, Africa & The Middle East

8.1 Brazil

8.2 Mexico

8.3 Rest of Latin America

8.4 Africa and The Middle East

9. Global Market Summary

9.1 Global

10. Potential Market Opportunity Sizes

10.1 Cancer Screening by Country: Lung, Breast & Colorectal

10.2 Cancer Screening by Country: Prostate, Other Cancer & All Cancer

10.3 Potential Market Size - Cancer Diagnosis

10.4 Potential Market Size - Cancer Management

For more information about this report visit http://www.researchandmarkets.com/research/v2tplr/circulating_tumor

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets